AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$GPCR

Structure Therapeutics Inc.

Price · $GPCRvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $GPCR in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $GPCR in the last 30 days.

Top stories · $GPCRMore →
MAR 17·MeykaMed

William Blair, Leerink Maintain Outperform on Structure Therapeutics (GPCR) Mar 2026

William Blair and Leerink Partners both maintained an "Outperform" rating on Structure Therapeutics (GPCR) on March 16, 2026, citing strong conviction in the company's oral GLP-1 program, aleniglipron. Despite modest intraday share declines, analysts emphasized the considerable market opportunity and clinical differentiation, without issuing new price targets. Investors are advised to view these ratings as affirmation of potential rather than immediate buy signals, awaiting further clinical readouts and commercialization details.

MAR 16·Seeking Alpha

Structure Therapeutics rises on mid-stage data for oral GLP-1

Structure Therapeutics (GPCR) saw its stock rise by approximately 8% following the release of positive topline phase 2 data for its oral GLP-1 receptor agonist, leniglipron, indicated for obesity. The promising results were derived from the 44-week ACCESS II study and interim data from another ongoing study.

DEC 12·Yahoo Finance

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

Structure Therapeutics Inc. announced the closing of an upsized public offering, raising approximately $747.5 million from the sale of American depositary shares (ADSs) and pre-funded warrants. The offering included the full exercise of the underwriters' option to purchase additional ADSs. This significant capital infusion will support the company's work in developing novel oral small molecule therapeutics.

News on $GPCR

All news →